Fatty acids analogous
The present invention relates to novel fatty acid analogous of the general formula (I): R 1 —[x i —CH 2 ] n —COOR 2 wherein R 1 is: a C 6 -C 24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C 6 -C 24 alkyne, and/or a C 6 -C 24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 2 -C 5 acyloxy or C 1 -C 4 alkyl, and wherein R2 represents hydrogen or C 1 -C 4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR 2 , and wherein X i independent of each other are selected from the group comprising O, S, SO, SO 2 , Se and CH 2 , and with the proviso that at least one of the X i is not CH 2 , and with the proviso that if R1 is an alkye, then the carbon-carbon triple bond is positioned between the (ω-1) carbon and the (ω-2) carbon, or between the (ω-2) carbon and the (ω-3) carbon, or between the (ω-3) carbon and the (ω-4) carbon, a salt, prodrug or complex thereof, which can be used for the treatment and/or prevention of syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis. Further, the invention relates to a nutritional composition comprising said fatty acid analogues, and a method for reducing the total weight, or the amount of adipose tissue in an animal.
1. A method for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto, an effective amount of a composition comprising a compound according to the general formula (I):
R 1 —[X—CH 2 ] n —COOR 2
wherein R 1 is;
a CH 3 —R 3 , wherein R 3 is a C 5 -C 24 alkene with one or more double bonds,
a CH 6 -C 24 alkyne, with one or more triple bonds, or
a C 6 -C 24 alkyl substituted in one or more positions with one or more substituents chosen from fluoride, chloride, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, and C 2 -C 5 acyloxy, and
wherein R 2 represents hydrogen or C 1 -C 4 alkyl,
wherein n is an integer from 1 to 12, and
wherein X are independently chosen from S, SO, SO 2 , Se and CH 2 , with the proviso that at least one of the X is not CH 2 , and
with the proviso that if R 1 is an alkyne, then at least one carbon-carbon triple bond is positioned between the (ω-1) carbon and the (ω-2) carbon, or between the (ω-2) carbon and the (ω-3) carbon, or between the (ω-3) carbon and the (ω-4) carbon,
or a pharmaceutically acceptable salt thereof.
2. A fatty acid analogue, wherein the fatty acid analogue is 3-thia-15-heptadecynoic acid or a pharmaceutically acceptable salt, or prodrug thereof.
3. A process for the preparation of a non-β-oxidizable fatty acid analogue according to claim 2 , comprising:
preparation of 11-bromo-1 (tetrahydro-2-pyranyloxy)undecane by reacting pyridine toluene 4-sulphonate and 11-bromo-1-undecanol with 3,4-dihydro-2H-pyran;
adding the 11-bromo-1-undecanol with 3,4-dihydro-2H-pyran to a solution comprising propyne gas, MeLi and diethyl ether to yield 14-(tetrahydro-2H-pyranoyl)-2-tetradecyne;
hydroxylation of the 14-(tetrahydro-2H-pyranoyl)-2-tetradecyne using ethanol in a suitable organic solvent to yield 12 tetradecyn-1-ol;
preparation of 14-bromo-2-tetradecyne by reacting the 12-tetradecyn-1-ol dissolved in hexane with pyridine and PBr 3 ;
preparation of 3-thia-15-heptadecynoic acid by reacting the 14-bromo-2-tetradecyne with KOH and thioglycolic acid in methanol.
4. A method for the treatment of a condition chosen syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis comprising administering to a patient in need thereof, an effective amount of a composition comprising a compound according the general formula (I):
R 1 —[X—CH 2 ] n —COOR 2
wherein R 1 is;
a CH 3 —R 3 , wherein R 3 is a C 5 -C 24 alkene with one or more double bonds,
a C 6 -C 24 alkyne, with one or more triple bonds, or
a C 6 -C 24 alkyl substituted in one or more positions with one or more substituents chosen from fluoride, chloride, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, and C 2 -C 5 acyloxy, and
wherein R 2 represents hydrogen or C 1 -C 4 alkyl, wherein n is an integer from 1 to 12, and
wherein X are independently chosen from S, SO, SO 2 , Se and CH 2 , with the proviso that at least one of the X is not CH 2 , and
with the proviso that if R 1 is an alkyne, then at least one carbon-carbon triple bond is positioned between the (ω-1) carbon and the (ω-2) carbon, or between the (ω-2) carbon and the (ω-3) carbon, or between the (ω-3) carbon and the (ω-4) carbon,
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising the compound according to claim 2 , and a pharmaceutically acceptable carrier.
6. A nutritional composition comprising the compound according to claim 2 , and a nutritionally acceptable carrier.
7. A method for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto, and effective amount of a composition comprising the compound according to claim 2 .
8. A method for the treatment of a condition chosen syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis comprising administering to a patient in need thereof, an effective amount of a composition comprising the compound according to claim 2 .
9. The method according to claim 1 , wherein the R 1 moiety comprises one carbon-carbon triple bond.
10. The method according to claim 1 , wherein the R 1 moiety comprises one carbon-carbon double bond.
11. The method according to claim 1 , wherein the X is sulfur.
12. A The method according to claim 1 , wherein the X is selenium.
13. A The method according to claim 1 , wherein the carbon-carbon double bond is in a cis configuration.
14. A The method according to claim 13 , wherein said carbon-carbon double bond is in the 9-position.